Organogenesis Holdings Inc.
ORGO
Price:
$2.47
Market Cap:
$327.46M
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediat...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2017-01-05
Stock Exchange
NASDAQ
Ticker
ORGO
The ROE as of September 2024 (TTM) for Organogenesis Holdings Inc. (ORGO) is -2.77%
According to Organogenesis Holdings Inc.’s latest financial reports and current stock price. The company's current ROE is -2.77%. This represents a change of 263.11% compared to the average of -0.76% of the last 4 quarters.
Organogenesis Holdings Inc. (ORGO) Historical ROE (quarterly & annually)
How has ORGO ROE performed in the past?
The mean historical ROE of Organogenesis Holdings Inc. over the last ten years is -17.00%. The current -2.77% ROE has changed -83.69% with respect to the historical average. Over the past ten years (40 quarters), ORGO's ROE was at its highest in in the September 2020 quarter at 31.97%. The ROE was at its lowest in in the September 2019 quarter at -83.86%.
Average
-17.00%
Median
0%
Minimum
-137.82%
Maximum
38.92%
Organogenesis Holdings Inc. (ORGO) ROE by Quarter and Year
Discovering the peaks and valleys of Organogenesis Holdings Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 19.51%
Maximum Annual ROE = 38.92%
Minimum Annual Increase = -Infinity%
Minimum Annual ROE = -137.82%
| Year | ROE | Change |
|---|---|---|
| 2023 | 1.77% | -69.65% |
| 2022 | 5.85% | -84.98% |
| 2021 | 38.92% | 229.91% |
| 2020 | 11.80% | -116.21% |
| 2019 | -72.78% | -47.19% |
| 2018 | -137.82% | 19.51% |
| 2017 | -0.70% | 910.37% |
| 2016 | -0.07% | -Infinity% |
Organogenesis Holdings Inc. (ORGO) Average ROE
How has ORGO ROE performed in the past?
The current ROE of Organogenesis Holdings Inc. (ORGO) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
15.51%
5-year avg
-2.89%
10-year avg
-17.00%
Organogenesis Holdings Inc. (ORGO) ROE vs. Peers
How is ORGO’s ROE compared to its peers?
Organogenesis Holdings Inc.’s ROE is greater than Shuttle Pharmaceuticals Holdings, Inc. (-217.58%), greater than Mallinckrodt plc (-117.04%), greater than Lucy Scientific Discovery Inc. (-377.80%), greater than Alimera Sciences, Inc. (-33.70%), less than Lifecore Biomedical, Inc. (26.37%), less than RedHill Biopharma Ltd. (1.86%), less than Taro Pharmaceutical Industries Ltd. (3.05%), less than Collegium Pharmaceutical, Inc. (49.14%), less than Adamis Pharmaceuticals Corporation (0.93%), greater than Alpha Teknova, Inc. (-38.94%), greater than Guardion Health Sciences, Inc. (-71.26%), greater than Petros Pharmaceuticals, Inc. (-134.64%), less than Alkermes plc (22.66%), less than Neurocrine Biosciences, Inc. (14.86%), greater than Intra-Cellular Therapies, Inc. (-11.48%), greater than Deciphera Pharmaceuticals, Inc. (-52.42%), less than Dynavax Technologies Corporation (2.76%),
| Company | ROE | Market cap |
|---|---|---|
| -217.58% | $3.42M | |
| -117.04% | $4.52M | |
| -377.80% | $906.91K | |
| -33.70% | $302.38M | |
| 26.37% | $147.38M | |
| 1.86% | $11.96M | |
| 3.05% | $1.62B | |
| 49.14% | $1.20B | |
| 0.93% | $7.25M | |
| -38.94% | $244.66M | |
| -71.26% | $17.02M | |
| -134.64% | $3.27M | |
| 22.66% | $4.42B | |
| 14.86% | $12.13B | |
| -11.48% | $7.77B | |
| -52.42% | $2.21B | |
| 2.76% | $1.45B |
Build a custom stock screener for Organogenesis Holdings Inc. (ORGO) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Organogenesis Holdings Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Organogenesis Holdings Inc. (ORGO) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Organogenesis Holdings Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Organogenesis Holdings Inc.'s ROE?
How is the ROE calculated for Organogenesis Holdings Inc. (ORGO)?
What is the highest ROE for Organogenesis Holdings Inc. (ORGO)?
What is the 3-year average ROE for Organogenesis Holdings Inc. (ORGO)?
What is the 5-year average ROE for Organogenesis Holdings Inc. (ORGO)?
How does the current ROE for Organogenesis Holdings Inc. (ORGO) compare to its historical average?